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Context (117/80-120) 
More than 500,000 percutaneous coronary intervention (PCI) procedures are 
performed worldwide each year for stable coronary artery disease (CAD). In addition 
to medical therapy, physiologically-targeted PCI reduces urgent revascularization in 
this group [1] but, unlike in acute coronary syndromes, evidence supporting a 
reduction in myocardial infarction and mortality is lacking [2], especially in those 
with low ischaemic burden [3]. Consequently, in stable CAD, PCI is used 
predominantly for symptomatic relief. It is therefore remarkable that, 40 years after 
ŶĚƌĞĂƐ 'ƌƺŶƚǌŝŐ ?Ɛfirst PCI, we only now have results of the first double-blind, 
placebo-controlled trial of PCI in stable angina; the ORBITA (Objective Randomised 
Blinded Investigation with optimal medical Therapy of Angioplasty in stable angina) 
trial [4]. 
 
Methods (149/100-150) 
Patients with stable angina and single-vessel disease underwent symptomatic and 
clinical assessment before and after a six-week phase of intensive anti-anginal 
therapeutic optimisation. Prior to randomisation, patients underwent 
cardiopulmonary exercise testing (CPET) and dobutamine stress echocardiography 
(DSE). Two hundred patients were randomised 1:1, to PCI or a sham PCI. 
Randomised patients underwent repeat invasive angiography with intra-coronary 
physiological (pressure-wire) assessment. The study was fully blinded. Operators 
were unaware of the physiological findings. Patients, were sedated and wore 
headphones during the procedure were unaware of whether they had undergone 
PCI or not. All patients were treated as though they had undergone PCI. After six 
weeks, patients underwent repeat clinical assessment including CPET and DSE by 
blinded researchers. The study was powered to detect the primary end point which 
was a between-group difference in incremental exercise time of t30 seconds. 
Analysis was on an intention-to-treat basis. 
 
Findings (92/75-100) 
105 patients were randomised to PCI and 95 to placebo. Baseline characteristics 
were similar; 98% had Canadian Cardiovascular Society class II or III angina and >90% 
had normal left ventricular function. At follow up, there was no statistically 
significant between-group difference in exercise time increase, time to 1mm ST 
depression, peak oxygen uptake, or angina symptoms scores. Exercise time 
increased by 28.4 s in the PCI group and 11.8 s in the placebo group (between-group 
comparison P=NS). The DSE peak stress wall motion score index improved more with 
PCI than placebo (<0.0001). 
 
Commentary (302/250-300) 
ORBITA was a commendable study in many respects. The investigators had the 
courage and motivation to perform an elegant randomised-controlled trial of a 
therapy widely accepted to be effective, despite funding challenges [5]. The study 
design was exemplary, especially in terms of the intensive, guideline-directed 
optimisation of medical therapy and the blinding of researchers and patients 
throughout the trial. The inclusion of sham PCI was innovative and the incorporation 
of multiple objective endpoints rigorous. However, some aspects of its conduct were 
unlike real-world practice. During the initial therapeutic optimisation phase, patients 
had up to three consultations with a consultant cardiologist per week and direct 
access at any time. In fact, therapeutic optimisation was so effective that 11% of 
included patients were free from angina at randomisation and would not therefore 
have qualified for PCI in most healthcare systems. Nearly one third of randomised 
patients had no physiological evidence of ischaemia (negative pressure-wire 
assessment) which, according to guidelines, should not be intervened upon and 
should be treated medically. Baseline exercise times were notably high, more so in 
the PCI group. Prospective power calculations were appropriate, but the exercise 
time results suggest (retrospectively) the sample size may have been too small to 
definitively detect the primary outcome. Few patients underwent ST depression 
analysis. The authors themselves highlight that drug intolerance or patient choice 
may still favour PCI over pharmacotherapy. Furthermore, ORBITA only included 
patients with stable, single-vessel disease and results should not be extrapolated to 
more advanced CAD. Finally, with six weeks follow up, this symptoms-focussed study 
was too short to assess longer term effects such as myocardial infarction and 
mortality.   
 
Implications for practice (72/50) 
ORBITA highlights the importance of ensuring patients actually receive optimal 
medical therapy in stable, single vessel disease, the need for improved and rigorous 
coronary physiological assessment, and a refreshing approach to study design. 
Interventional cardiologists are likely to defer changing practice significantly until the 
results of the much larger ISCHEMIA trial (NCT01471522) are known, a study of 
>5000 patients with stable CAD which is assessing long term prognostic benefit. 
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